Compare NPCE & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NPCE | ADCT |
|---|---|---|
| Founded | 1997 | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 432.3M | 484.4M |
| IPO Year | 2021 | 2019 |
| Metric | NPCE | ADCT |
|---|---|---|
| Price | $15.61 | $4.25 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 4 |
| Target Price | ★ $18.33 | $7.75 |
| AVG Volume (30 Days) | 165.9K | ★ 741.8K |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 29.03 | ★ 30.86 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $99,986,000.00 | $81,357,000.00 |
| Revenue This Year | $0.90 | N/A |
| Revenue Next Year | $24.46 | $66.49 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 25.13 | 14.85 |
| 52 Week Low | $7.56 | $1.20 |
| 52 Week High | $18.97 | $4.98 |
| Indicator | NPCE | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 63.20 | 65.47 |
| Support Level | $15.25 | $3.28 |
| Resistance Level | $15.71 | $4.71 |
| Average True Range (ATR) | 0.67 | 0.25 |
| MACD | 0.22 | 0.07 |
| Stochastic Oscillator | 93.71 | 91.51 |
NeuroPace Inc is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of seizures. The company offers the RNS System, a brain-responsive neuromodulation system that continuously monitors and analyzes the brain's electrical activity and delivers personalized, real-time electrical pulses at the seizure source to prevent seizures. The RNS System includes the RNS neurostimulator, cortical strip leads, depth leads, a Patient Remote Monitor, and other implantable and non-implantable accessories used during implant procedures. The company also provides the Physician Tablet, Patient Data Management System, and the nSight Platform to facilitate ongoing patient monitoring and support clinicians in managing patient care.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).